Instant Access to Deep Knowledge on Pharmaceutical Drugs

Single User Lite

One User

► Instant Access

US Patent Data
 Most Popular

Single User

One User

► Instant Access

US & International Patent Data
Email Alerts
Suppliers and Formulation
 Optional Expired Patents
Data Export
 For Teams


Unlimited users

► Inquire

US & International Patent Data
Email Alerts
Suppliers and Formulation
Expired Patents Included
Data Export

Request a Callback

Name: *
Email: *
Company: *
Telephone: *

Pick Your Plan

 Most Popular  For Teams
Feature Single User Lite Single User Enterprise
International Patent Data -
Supplementary Protection Certificates (SPCs) -
Orange Book Patents
Non-Orange Book Patents -
Expired Patents (1986 - Present) - optional add-on ($995/yr) included
Detailed Patent Information -
Detailed Regulatory Status
Paragraph IV Challenges -
Tentative Approvals (indicates impending generic entry) -
Authorized Generics -
Drug Master File Listings -
Drug Information
Comprehensive Drug Information
Suppliers -
Formulation -
Manufacturing -
Drug Class
Additional Features
Email Alerts -
Data Export -
Dynamic Trend Graphs -
Users 1 1 Unlimited
Price / Year $2,495 $2,995 Inquire
  Additional Users  $749  $899 Free

Frequently Asked Questions

DrugPatentWatch has patent coverage for the following countries and regional organizations:

African Intellectual Property Organization (OAPI) African Regional IP Organization (ARIPO) Algeria Argentina Australia Austria Bahrain (GCC) Belgium Benin (OAPI) Bosnia and Herzegovina Botswana (ARIPO) Brazil Bulgaria Burkina Faso (OAPI) Cameroon (OAPI) Canada Central African Republic (OAPI) Chad (OAPI) Chile China Colombia Comoros (OAPI) Congo-Brazzaville (OAPI) Costa Rica Croatia Cuba Cyprus Czech Republic Czechoslovakia Côte d'Ivoire (OAPI) Denmark Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea (OAPI) Estonia Eurasian Patent Organization European Patent Office Finland France Gabon (OAPI) Georgia, Republic of German Democratic Republic Germany Ghana (ARIPO) Greece Guatemala Guinea (OAPI) Guinea-Bissau (OAPI) Gulf Cooperation Council Honduras Hong Kong Hungary Iceland India Indonesia Ireland Israel Italy Japan Jordan Kenya (ARIPO) Kuwait (GCC) Latvia Lesotho (ARIPO) Liberia (ARIPO) Lithuania Luxembourg Malawi (ARIPO) Malaysia Mali (OAPI) Mauritania (OAPI) Mexico Moldova, Republic of Monaco Montenegro Morocco Mozambique (ARIPO) Namibia (ARIPO) Netherlands New Zealand Nicaragua Niger (OAPI) Norway Oman (GCC) Panama Peru Philippines Poland Portugal Qatar (GCC) Romania Russian Federation Rwanda (ARIPO) San Marino Saudi Arabia (GCC) Senegal (OAPI) Serbia Sierra Leone (ARIPO) Singapore Slovakia Slovenia Somalia (ARIPO) South Africa South Korea Spain Sudan (ARIPO) Swaziland (ARIPO) Sweden Switzerland São Tomé and Príncipe (ARIPO) Taiwan Tajikistan Tanzania (ARIPO) The Gambia (ARIPO) Togo (OAPI) Tunisia Turkey Uganda (ARIPO) Ukraine United Arab Emirates (GCC) United Kingdom United States of America Uruguay Viet Nam Yugoslavia Zambia (ARIPO) Zimbabwe (ARIPO)

Adding an alert is as easy as clicking the 'Add Alert' button on a page of interest.

    Available alerts include:

  • Paragraph IV challenges
  • New drugs and added or expired patents per company
  • Added or expired patents per drug
  • Tentative approvals

The Enterprise Plan enables unlimited users (identified by IP blocks), within your organization. The Single User plans cannot be shared, but multiple accounts can be purchased for a substantial discount.

Please use the contact form and tell us which subscription plan you would like an invoice for.

No problem. Please use the contact form and let us know how we can be of assistance.

Trusted by Industry Leaders

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Fortune- Generics' new legal attack: Big Pharma's aging patents CNN Money - Generics' new legal attack: Big Pharma's aging patents New England Journal of Medicine Barrons

Globalization of Pharmaceutical Drug Innovation The structure and business of biopharmaceutical companies including the management of risks and resources Drug Topics Nature Biotechnology Business Insider National Bureau of Economic Research

For more information try a trial or see the database preview.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Related Products from thinkBiotech

Connect with Social Media: